C. Polman

Publications781
h-index119
Citations75,037
Highly Influential Citations2,920
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • F. Barkhof
  • 2,076 Publications • 108,994 Citations
  • M. Filippi
  • 1,917 Publications • 89,614 Citations
  • D. Miller
  • 489 Publications • 45,033 Citations
  • A. Thompson
  • 635 Publications • 78,246 Citations
  • Publications
  • Influence
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
TLDR
These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
TLDR
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
TLDR
New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
TLDR
Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
TLDR
Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Defining the clinical course of multiple sclerosis
TLDR
Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
TLDR
It is concluded that a four-parameter dichotomized MRI model including gadolinium-enhancement, juxtacortical, infratentorial and periventricular lesions best predicts conversion to clinically definite multiple sclerosis.
Differential diagnosis of suspected multiple sclerosis: a consensus approach
Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings. A systematic process for exclusion of…
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
TLDR
It is reported that the susceptibility allele near IRF8, which encodes a transcription factor known to function in type I Interferon signaling, is associated with higher mRNA expression of interferon-response pathway genes in subjects with MS.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
TLDR
In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis and both measures decreased in patients who switched from placebo to fingolIMod.
...
1
2
3
4
5
...